IJR News — today's news from every sideMaya Lindstrom Larson on pole is fine by me since he has been the best car lately and the points system puts the right guys up front. Sam Okafor Late contact at Bristol always leads to hard feelings. They settled it quick and now it's time to race again. Marcus Bell Larson had a strong run but Logano just had the better car when it mattered most. Nicole Hardy Blaney showing up with that black eye proves the Bristol fight was no joke, but NASCAR skipping penalties keeps the focus on racing. Jared Kim Creed's late pass on that restart showed why he's leading the points, weather or not. Rachel Meyers Preston's home form has been dire, if Blackburn nick it there it could get really tense on the terraces. Cullen Capital Expands Stakes Across AXTA, CLX — Aug 25, 2026Cullen Capital Management LLC disclosed new Q2 positions in five companies, acquiring Axalta Coating Systems, The Clorox Company, Bristol Myers Squibb, Copa Holdings, and Veralto Corporation for substantial sums. The investments spanned diverse sectors—chemicals, consumer goods, biotech, travel, and water-treatment—highlighting a broad, active portfolio expansion with specific share counts and values reported in the filings.
Devon father jailed for life over baby's death — Jul 24, 2026Tony Bartlett, 39, of Axminster, Devon, has been jailed for life with a minimum term of 18 years for murdering his four-week-old son Atticus in Chard, Somerset, after a night out drinking; prosecutors said his intoxication and anger caused a violent shake that led to fatal brain and spinal injuries. The case, heard at Bristol Crown Court, also highlighted details of the evening out and the baby’s injuries, with Ballentyne, Atticus’s mother, not charged in connection with the death.
BMS to Build $2.3B Houston Campus; Lilly Expands — Aug 10, 2026Bristol Myers Squibb is investing about $2.3 billion to build a 600,000-square-foot modular, multi-modal manufacturing campus at Generation Park in Houston, part of its $40 billion five-year U.S. investment plan, to produce small molecules, biologics, and antibody-drug conjugates while enabling future expansion. The project will create roughly 500 permanent jobs and about 2,000 construction roles through 2030, supported by Texas incentives, as drugmakers continue expanding domestic manufacturing under government pressure to boost U.S. production.
